- $207.37m
- $208.33m
- $66.58m
Exagen Inc. reports results for the quarter ended June 30 - Earnings Summary
Exagen Q2 revenue beats on test volume growth; raises 2026 outlook
Exagen Inc expected to post a loss of 19 cents a share - Earnings Preview
Exagen beats Q1 revenue estimates, reaffirms 2026 guidance
Brief: Exagen Inc. Q1 Revenue USD 17.306 Million Vs. IBES Estimate USD 16.4 Million
Exagen Q4 revenue slightly beats expectations
Exagen Q3 revenue beats analyst expectations
Exagen Inc reports results for the quarter ended June 30 - Earnings Summary
Autoimmune diagnostic test maker Exagen Q2 revenue up more than expected
Exagen Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Exagen Appoints Chas Mckhann To Board Of Directors
Brief: Michael Mahler, Phd Joins Exagen As Chief Scientific Officer To Enhance Leadership In Autoimmune Diagnostics
Brief: Exagen files prospectus related to resale of up to 1.2 mln shares
U.S. STOCKS ON THE MOVE-MercadoLibre, Crocs, Paycom Software
U.S. STOCKS ON THE MOVE-Tapestry, Carvana, PPG Industries
Brief: Exagen Inc. Prices Public Offering Of Common Stock At $5.25 Per Share
U.S. STOCKS ON THE MOVE-AppLovin, Appian, Axon
Exagen tumbles on stock sale
Exagen falls after stock sale launch